Mn Services Vermogensbeheer B.V. Sells 3,100 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mn Services Vermogensbeheer B.V. lowered its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 5.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 52,900 shares of the company’s stock after selling 3,100 shares during the quarter. Mn Services Vermogensbeheer B.V. owned approximately 0.06% of Neurocrine Biosciences worth $5,619,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NBIX. Acadian Asset Management LLC acquired a new position in shares of Neurocrine Biosciences in the first quarter valued at approximately $27,000. Covestor Ltd increased its position in Neurocrine Biosciences by 431.0% during the 1st quarter. Covestor Ltd now owns 377 shares of the company’s stock valued at $35,000 after purchasing an additional 306 shares during the period. First Horizon Advisors Inc. increased its position in Neurocrine Biosciences by 37.6% during the 2nd quarter. First Horizon Advisors Inc. now owns 699 shares of the company’s stock valued at $67,000 after purchasing an additional 191 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $95,000. Finally, Wipfli Financial Advisors LLC acquired a new stake in Neurocrine Biosciences during the 3rd quarter valued at approximately $101,000. Institutional investors own 92.58% of the company’s stock.

Insider Activity

In other news, insider Darin Lippoldt sold 4,923 shares of the firm’s stock in a transaction on Thursday, October 27th. The stock was sold at an average price of $115.04, for a total transaction of $566,341.92. Following the completion of the sale, the insider now directly owns 29,234 shares of the company’s stock, valued at approximately $3,363,079.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Darin Lippoldt sold 4,923 shares of Neurocrine Biosciences stock in a transaction dated Thursday, October 27th. The stock was sold at an average price of $115.04, for a total value of $566,341.92. Following the completion of the sale, the insider now owns 29,234 shares of the company’s stock, valued at approximately $3,363,079.36. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Eric Benevich sold 24,593 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, November 8th. The stock was sold at an average price of $125.33, for a total value of $3,082,240.69. Following the completion of the sale, the insider now directly owns 15,643 shares of the company’s stock, valued at approximately $1,960,537.19. The disclosure for this sale can be found here. Insiders sold a total of 139,534 shares of company stock valued at $17,059,059 in the last ninety days. 4.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on NBIX. Piper Sandler increased their target price on shares of Neurocrine Biosciences from $91.00 to $103.00 and gave the company a “neutral” rating in a research report on Wednesday, November 2nd. BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $78.00 to $101.00 in a research report on Wednesday, November 2nd. TheStreet raised shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research report on Tuesday, November 1st. SVB Leerink raised their price objective on shares of Neurocrine Biosciences from $100.00 to $115.00 and gave the stock a “market perform” rating in a research report on Wednesday, November 2nd. Finally, Cantor Fitzgerald raised their price objective on shares of Neurocrine Biosciences from $127.00 to $132.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 2nd. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $122.24.

Neurocrine Biosciences Trading Down 0.5 %

Shares of NASDAQ:NBIX opened at $108.99 on Tuesday. The stock’s fifty day simple moving average is $118.98 and its two-hundred day simple moving average is $109.69. Neurocrine Biosciences, Inc. has a 1-year low of $72.28 and a 1-year high of $129.29. The stock has a market cap of $10.48 billion, a PE ratio of 191.21 and a beta of 0.54.

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last announced its earnings results on Tuesday, November 1st. The company reported $0.69 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.15). Neurocrine Biosciences had a net margin of 4.19% and a return on equity of 4.06%. The business had revenue of $387.90 million for the quarter, compared to analysts’ expectations of $378.05 million. On average, sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 1.93 earnings per share for the current fiscal year.

Neurocrine Biosciences Company Profile

(Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.